Regenerative Medicines Market 2018-2023, by Cell-Based, Acellular Products, And Application

Global regenerative medicines market is expected to reach USD 54.88 billion by 2023 from USD 17.20 billion in 2018, growing at a CAGR of 23.24% during the forecast period 2018-2023.

Regenerative medicines repair, replace or regenerate human cells, tissues, or organs affected due to injury, disease, aging processes, congenital defects, and damage due to trauma. These medicines restore normal functions of cells & tissues. These medicines are available in different types such as genes, somatic cells, stem cells, and other types. Some of these medicines (such as stem cells) have the ability to proliferate, differentiate thereby restore the original structure of cells or tissues or organs. Regenerative medicines are used in varied range of degenerative disorders include cardiovascular, neurodegenerative diseases, dermatology, and orthopedic, among others. Majority of the researchers aim to focus on the development of innovative technologies to provide better regenerative medicines and effective healthcare treatment solutions to patients.

Request a Sample Brochure! Get PDF Sample Copy@ http://www.orbisresearch.com/contacts/request-sample/2290058

Rising demand for biologically derived materials for regenerative medicine, growing technological advancements (nanotechnology based tissue engineering), and high support from government to promote the tissue engineering for the development of advanced therapies are driving the growth of global regenerative medicines market. In addition, growing utilization of regenerative medicines in cancer research & drug discovery, increasing organ transplantations, and rising healthcare expenditure are further stimulating the growth of global regenerative medicines market. However, presence of stringent regulatory pathways for tissue engineered products & cell-based products, strict ethical regulations for the utilization of human tissue, certain post-implantation infections & complications, and high cost for the research & development of cell-based products (such as stem cells).

Global regenerative medicines market is segmented based on product, therapy, and application. Based on product, the market is further sub-segmented as cell-based products and acellular products. Of these, cell-based products segment is estimated to account for larger share of the global regenerative medicines market by product in 2018. Further, Cell-based products segment is classified as autologous and allogeneic products. Based on therapy, the market is segmented as cell therapy, gene therapy, tissue engineering, and immunotherapy. Of these, cell therapy is estimated to command the highest share of the global regenerative medicines market by therapy in 2018.

Based on application, the market is segmented as orthopedic & musculoskeletal spine, dermatology, central nervous system, cardiovascular, oncology, diabetes, and other applications. Among these, orthopedic & musculoskeletal spine is estimated to command the largest share of the global regenerative medicines market by application in 2018.

On the basis of geographical region the global regenerative medicines market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is estimated to command the highest share of 31.3% of the global regenerative medicines market in 2018, whereas Asia-Pacific is estimated to grow at the highest CAGR of 28.90% during the forecast period 2018-2023.

The key players in global regenerative medicines market such as, Vertex Pharmaceuticals Incorporated (U.S.), Acelity L.P. Inc. (U.S.), Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), Cytori Therapeutics Inc. (U.S.), Advantagene, Inc. (U.S.), and Mesoblast Ltd. (Australia).

Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail

To make an enquiry on report@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2290058

Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics

Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis

Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development

A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment

Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies

An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions

Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

Some Point from Table of Content:

1.Introduction

2.Research Methodology

3.Overview

4.Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

5.Market Segmentation

6.Geographical Analysis

7.Strategic Analysis

8. Market Leaders' Analysis

8.1 Vertex Pharmaceuticals Incorporated (U.S.)

8.1.1 Overview

8.1.2 Product Analysis

8.1.3 Strategic Evaluation and Operations

8.1.4 Financial analysis

8.1.5 Legal issues

8.1.6 Recent Developments

8.1.7 SWOT analysis

8.1.8 Analyst View

8.2 Acelity L.P. Inc. (U.S.)

8.3 Celgene Corporation (U.S.)

8.4 StemCells, Inc. (U.S.)

8.5 Organogenesis Inc. (U.S.)

8.6 NuVasive, Inc. (U.S.)

8.7 Vericel Corporation (Genzyme) (U.S.)

8.8 Cytori Therapeutics Inc. (U.S.)

8.9 Advantagene, Inc. (U.S.)

8.10 Mesoblast Ltd. (Australia)

9. Competitive Landscape

9.1 Market share analysis

9.2 Merger and Acquisition Analysis

9.3 Agreements, collaborations and Joint Ventures

9.4 New Product Launches

10. Expert Opinions

10.1 Market Outlook

10.2 Investment Opportunities

Appendix

a) List of Tables

b) List of Figures

Click to read more@ http://www.orbisresearch.com/reports/index/regenerative-medicines-market-by-product-cell-based-and-acellular-products-therapy-and-application-global-market-analysis-size-geographic-regional-analysis-competitive-strategies-analysis-and-forecasts-2018-to-2023.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas - 75204, U.S.A.

Phone No: +1 (214) 884-6817; +912064101019

Email ID: sales@orbisresearch.com

This release was published on openPR.